10 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS (LIVERHOPE)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact in patients quality of life and represents a major burden for health systems. Treatment of cirrhosis is currently based on symptomatic management of complications and has not changed substantially in the last 20 years. There is an unmet need for therapies tha ...
Voir le projet
18
Participants partenaires
TERMINÉ
Early warning signals of ageing in human stem cells and age-related disorders (SYSTEMAGE)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
The regenerative power of a living organism is linked to the potential of its stem cells to replace the corresponding damaged tissue. Therefore organisms are as old as their stem cells. Whereas the vulnerability to cancer and chronic inflammation is associated with a decline of the immune system, the latter is in turn a sum product of interactions among hematopoietic stem cells (HSC), endothelial ...
Voir le projet
11
Participants partenaires
TERMINÉ
"King of hearts, joints and lungs; periodontal pathogens as etiologic factor in RA, CVD and COPD and their impact on treatment strategies." (TRIGGER)
Date du début: 1 avr. 2013, Date de fin: 31 mars 2017,
"Extensive clinical and epidemiological data clearly shows that chronic periodontal disease (PD), the most prevalent infectious inflammatory disease of mankind, is strongly linked to systemic inflammatory diseases such as cardiovascular diseases (CVD) , rheumatoid arthritis (RA) , and chronic obstructive pulmonary disease (COPD) . Taking into account that up to 30% of the adult population worldwid ...
Voir le projet
11
Participants partenaires
TERMINÉ
Optimized oxidoreductases for medium and large scale industrial biotransformations (INDOX)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2016,
The INDOX proposal on industrial oxidoreductases aims to provide relevant industrial case stories to demonstrate the efficacy of optimized biocatalysts on targeted reactions, and to establish the processes scalability, sustainability and cost-efficiency versus chemical conversion processes. The chemical industry (specialties excluded) is not yet embracing enzymatic oxidation reactions to a signifi ...
Voir le projet
16
Participants partenaires
TERMINÉ
Prolonged inhibition of semaphorine3a pathway via a bio-degradable implant towards a better therapy for visual sensory impairments (VISION)
Date du début: 1 sept. 2012, Date de fin: 31 août 2016,
"The visual pathway is a component of the central nervous system (CNS) and therefore is not regenerative. Acute optic nerve injury, ischemic optic neuropathy and glaucoma are conditions that initially lead to partial blindness and eventually could lead to total blindness. Extensive neuron and retinal ganglion cells (RGC) death is evidenced in these pathologies. Semaphorin 3A (Sema3A) is a cell sec ...
Voir le projet
5
Participants partenaires
TERMINÉ
Rheumatoid Arthritis and Periodontal Inflammatory Disease (RAPID) (RAPID)
Date du début: 1 avr. 2012, Date de fin: 31 mars 2016,
"The most prevalent chronic inflammatory diseases of humans are complex disorders of multifactorial aetiology influenced by genes, the environment and their interactions. Periodontitis (PD) and rheumatoid arthritis (RA) are two such chronic inflammatory diseases associated withsignificant morbidity and mortality, and have recently shown to have a bi-directional association. Moreover, the prevalenc ...
Voir le projet
15
Participants partenaires
TERMINÉ
Identifying correlates of protection to accelerate vaccine trials: systems evaluation of two models of experimentally-induced immunity to malaria (SysMalVac)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2014,
Vaccine development is an empirical process (trial and error) and involves a long, expensive clinical development pipeline to license an efficacious vaccine candidate. Better tools for vaccine evaluation are needed to adapt to a rising number of candidate vaccines entering clinical trials for many diseases. Surrogate biomarkers of immunity offer the possibility of expediting the clinical developme ...
Voir le projet
8
Participants partenaires
TERMINÉ
A novel drug discovery method based on systems biology: combination therapy and biomarkers for Multiple Sclerosis (CombiMS)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2014,
The therapeutic challenge of complex diseases requires the use of combination therapies to target the distinct mechanisms and pathways involved. Such complex diseases will benefit from the design of computational models adopting a systems perspective to integrate the knowledge generated by ‘omics technologies and clinical data. Multiple Sclerosis is a prototypic debilitating complex disease in whi ...
Voir le projet
8
Participants partenaires
TERMINÉ
Protein citrullination as a link between periodontal diseases and rheumatoid arthritis (RA) and target for development of novel drugs to treat RA (GUMS AND JOINTS)
Date du début: 1 nov. 2010, Date de fin: 31 oct. 2014,
Autoimmunity in rheumatoid arthritis (RA) is characterised by an antibody response to citrullinated proteins. Periodontitis (PD) is largely caused by infection, in whichPorphyromonas gingivalis is a major pathogen. The two diseases combine specific HLA-DRB1alleles and smoking as risk factors, and have a similar pathophysiology characterised by destructive inflammation. A possible causative link be ...
Voir le projet
14
Participants partenaires
TERMINÉ
Identification and validation of novel drug targets in Gram-negative bacteria by global search: a trans-system approach (AntiPathoGN)
Date du début: 1 févr. 2009, Date de fin: 31 juil. 2013,
Multi-drug-resistant bacterial infections are increasing at an alarming pace in both developing and developed countries and in both community and nosocomial settings. The few antimicrobial agents that have been launched during the last decade (e.g. linezolid, daptomycin) have a good activity against Gram-positive bacteria. However, multi-drug-resistant bacteria are often found among the Gram-negat ...
Voir le projet